$95MSeries B, 24 September 2025
Funds the Phase 2b CAPTAIN-T2D trial, with data expected in 2027.
- Amount
- $95M
- Stage
- Series B
- Announced
- 24 September 2025
- Lead
- Forbion
- Other investors
- RA Capital Management, OrbiMed, RiverVest, US Venture Partners
- Use of funds
- Funds the Phase 2b CAPTAIN-T2D trial, with data expected in 2027.
- Checked
- Announced by the company
- Sources
- Sparrow Pharmaceuticals Announces $95 Million Series B Financing to Advance Targeted Therapy for Type 2 Diabet forbion.com
Sparrow Pharmaceuticals Announces $95 Million Series B Financing to Advance Targeted Therapy for Type 2 Diabet news.google.com